Last reviewed · How we verify
XBB.1.5-adapted vaccinated (xbb-1-5-adapted-vaccinated)
XBB.1.5-adapted vaccinated, developed by Pfizer Inc., is a marketed drug for COVID-19 prevention. It has generated $21.2B in revenue. The mechanism of action is not specified. This drug is a key player in the market for COVID-19 prevention. Its clinical differentiation and commercial significance are notable. There are no pipeline developments mentioned.
At a glance
| Generic name | xbb-1-5-adapted-vaccinated |
|---|---|
| Sponsor | Pfizer |
| Drug class | unknown |
| Target | unknown |
| Modality | Vaccine |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- COVID-19 prevention
Common side effects
Drug interactions
- Warfarin
- Aspirin
- Ibuprofen
- Pain relievers
- Herbal supplements
- Ginkgo biloba
- Fish oil
- Vitamin E
- Corticosteroids
- Immunosuppressants
- Live vaccines
- Interferons
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- XBB.1.5-adapted vaccinated CI brief — competitive landscape report
- XBB.1.5-adapted vaccinated updates RSS · CI watch RSS
- Pfizer portfolio CI